-
公开(公告)号：US20180000962A1
公开(公告)日：2018-01-04
申请号：US15592072
申请日：2017-05-10
Applicant: Genentech, Inc.
Inventor： Charles W. Eigenbrot, JR. , Jagath Reddy Junutula , Henry Lowman , Helga E. Raab , Richard Vandlen
CPC classification number: A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
-
Patent Agency Ranking
公开(公告)号：US20160145349A1
公开(公告)日：2016-05-26
申请号：US14948911
申请日：2015-11-23
Applicant: Genentech, Inc.
Inventor： Arthur Huang , Robert Kelley , Henry Lowman , Menno Van Lookeren Campagne , Charles Winter
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
Abstract translation: 本发明涉及抗因子D抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其生产及其在制备用于治疗与过量或不受控制的疾病和病症的组合物和药物的用途 补体激活。 这些抗体可用于疾病的诊断，预防和治疗。
-
公开(公告)号：US20190185579A1
公开(公告)日：2019-06-20
申请号：US16048002
申请日：2018-07-27
Applicant: Genentech, Inc.
Inventor： Arthur Huang , Robert Kelley , Henry Lowman , Menno Van Lookeren Campagne , Charles Winter
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
-
公开(公告)号：US09676868B2
公开(公告)日：2017-06-13
申请号：US14033175
申请日：2013-09-20
Applicant: GENENTECH, INC.
Inventor： Arthur Huang , Robert Kelley , Henry Lowman , Menno Van Lookeren Campagne , Charles Winter
IPC: C07K16/40 , A61K39/395 , C07K16/18 , A61K39/00
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
-
公开(公告)号：US20150017188A1
公开(公告)日：2015-01-15
申请号：US14152287
申请日：2014-01-10
Applicant: Genentech, Inc.
Inventor： Charles W. Eigenbrot, JR. , Jagath Reddy Junutula , Henry Lowman , Helga E. Raab , Richard Vandlen
CPC classification number: A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
Abstract translation: 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20140065137A1
公开(公告)日：2014-03-06
申请号：US14033175
申请日：2013-09-20
Applicant: GENENTECH, INC.
Inventor： Arthur Huang , Robert Kelley , Henry Lowman , Menno Van Lookeren Campagne , Charles Winter
IPC: C07K16/18
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
Abstract translation: 本发明涉及抗因子D抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其生产及其在制备用于治疗与过量或不受控制的疾病和病症的组合物和药物的用途 补体激活。 这些抗体可用于疾病的诊断，预防和治疗。
-
-
-
-
-
Search Results
6
records
(took 0.023 seconds)
